Your session is about to expire
← Back to Search
Vasodilator
Angiotensin 1-7 for Peripheral Arterial Disease
Phase < 1
Waitlist Available
Led By Amy C Arnold, PhD
Research Sponsored by Milton S. Hershey Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 50 minutes
Awards & highlights
Study Summary
This trial will test whether or not the hormone angiotensin-(1-7) can help treat peripheral arterial disease by improving blood vessel function and reducing inflammation.
Eligible Conditions
- Peripheral Arterial Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 50 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~50 minutes
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Tumor Markers
Leg Blood Flow
Secondary outcome measures
Blood Pressure
Heart Rate
Other outcome measures
Lipids
Nitric Oxide Bioavailability
Renin-Angiotensin System Hormones
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Angiotensin-(1-7)Experimental Treatment1 Intervention
Subjects will receive intravenous infusion of five ascending doses of angiotensin-(1-7). The doses are: 1, 2, 4, 8, and 12 ng/kg/min. Each dose will be maintained for 10 minutes, for a total infusion period of 50 minutes.
Group II: SalinePlacebo Group1 Intervention
Subjects will receive intravenous infusion of saline that is matched in volume to the angiotensin-(1-7) arm. Saline infusion will be maintained for a total infusion period of 50 minutes.
Find a Location
Who is running the clinical trial?
Milton S. Hershey Medical CenterLead Sponsor
497 Previous Clinical Trials
2,799,964 Total Patients Enrolled
6 Trials studying Peripheral Arterial Disease
357 Patients Enrolled for Peripheral Arterial Disease
Amy C Arnold, PhDPrincipal InvestigatorPenn State College of Medicine
2 Previous Clinical Trials
56 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are currently taking medications called serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors.You have a history of alcohol or drug abuse.You have difficulty making decisions and understanding information.You cannot have taken any experimental medications in the month before the study.You don't experience any pain or discomfort in your legs while resting or walking.You have a history or currently have a disease that affects your immune system or blood.You are currently taking medications called phosphodiesterase-5 inhibitors.You are currently taking blood thinning medications.
Research Study Groups:
This trial has the following groups:- Group 1: Angiotensin-(1-7)
- Group 2: Saline
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger